Compare GHG & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
Current Price
Current Price
| Metric | GHG | ACIU |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.0M | 221.9M |
| IPO Year | 2017 | 2015 |
| Metric | GHG | ACIU |
|---|---|---|
| Price | $1.10 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 6.3K | ★ 193.2K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.02 | $706.75 |
| Revenue Next Year | $8.26 | $321.13 |
| P/E Ratio | $5.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $2.03 |
| 52 Week High | $2.57 | $4.00 |
| Indicator | GHG | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 63.05 |
| Support Level | $1.10 | $2.51 |
| Resistance Level | $1.16 | $2.66 |
| Average True Range (ATR) | 0.02 | 0.13 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 28.57 | 87.96 |
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The Group reports its financial results in two operating segments: Hotel Business, which consists of leased-and-operated hotels and franchised-and-managed hotels operating under the hotel related brand, and Restaurant Business, which consists of leased-and-operated restaurants and franchised-and-managed restaurants operating under the brands of Da Niang and Bellagio. It derives maximum revenue from Hotel Business segment. It operates solely in China and generates all its revenue from China itself.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.